Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice.
about
Cell Therapy Products in Menopausal MedicineSafety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysisA review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.Bisphosphonates: do we know their role in adjuvant breast cancer treatment?Intravenous bisphosphonates for postmenopausal osteoporosis.Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational StudyMandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates.The role of galenic innovation in improving treatment compliance and persistence: three case studies.Osteoporosis and bisphosphonate-related osteonecrosis of the jaw bone.The relationship of frequency of meat consumption and osteoporosis in Chinese postmenopausal women.The effect of vitamin D and bisphosphonate on fracture healing: An experimental studyManagement of osteoporosis among the elderly with other chronic medical conditionsImpact of the training on the compliance and persistence of weekly bisphosphonate treatment in postmenopausal osteoporosis: a randomized controlled study.Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGShould bisphosphonates be utilized in the adjuvant setting for breast cancer?Clinically significant drug interactions with antacids: an update.The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.Benefits of investment into modern medicines in Central-Eastern European countries.Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence.Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment - a grossly underestimated risk?Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.Mandibular osteonecrosis due to bisphosphonate use.Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.Risedronate on two consecutive days per month.Effect of locally administered novel biodegradable chitosan based risedronate/zinc-hydroxyapatite intra-pocket dental film on alveolar bone density in rat model of periodontitis.Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries.Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.Comparison of antiresorptive effect of hormone therapy and ibandronate in postmenopausal osteoporotic women by assessing type I collagen C-telopeptide levels.
P2860
Q28076744-C69C35C8-1C23-4A86-BF8B-572A85C7168CQ28242783-63D9273C-1F9B-417C-9AF5-95BD62D4EFDFQ34016943-80E6C5D4-C3E1-4B4D-86F0-73F3FE79E597Q34529920-51F387DE-AEAC-4A94-BA5B-BA93DF325FA2Q34632094-6028FC70-85B8-419D-8399-0001B3010090Q34863964-4B47226C-7D9D-4B80-A5FB-0A11A1CB3723Q35371081-B4036587-884B-4852-A57C-8B7AAF217B1AQ35400080-1522DD8B-ADFF-46CD-92DA-5D8BC6E2E689Q35454381-CA70B50B-78EF-49B6-80C0-B1EB6883C597Q35687827-3C16C330-0F95-46D5-8C5B-0E06B309068CQ36493001-54F79DC0-A4DD-4FBB-85D1-85CFE8843587Q36871059-4A7ADD69-3F36-4A71-8C71-DB3BDA5120A7Q37156112-0C2955F7-1CEF-4F1A-95D5-8CE79443C8FEQ37376275-076AAED9-2BC7-4B97-B1D9-974FE0043E68Q37418209-8E371868-6A4F-407B-87C3-BC511083B05AQ37742180-949493C4-6BB1-4BBC-B8EF-DAEDCA6EE88EQ37758417-1E0B21BB-9C11-4E6F-8026-7A97846E58EDQ37937722-72C29A94-27C6-4871-A767-38F6BE8CD05CQ38006918-34528D6B-8353-477F-A9E5-F54FB50FD53AQ38172291-C50F3315-C533-4AA2-874A-69B77CCC2FA4Q38230010-4CB838C9-9FA7-480C-BD67-E15CFAE11BEBQ39527504-C6BF5C52-817E-41DE-9AB7-02A04E58A60DQ39942547-D3DAE5AE-4F53-4FCC-9F00-AA5DF70CB025Q42815837-2420F055-C1D0-4637-8794-B67E9C866471Q44114890-4C612BC2-1CE1-41D7-BE62-4FB6FC403ABFQ45992787-237CCBA5-835E-48F3-942B-4ABFF0F612A1Q48093661-72230CB5-8625-41E9-A225-992048124F85Q48167255-11F26C8F-BC7B-4EDC-9F0B-D7A8A5375148Q48545123-6A400A46-3F5E-43E3-901B-AEA1C92D5109Q55058946-E42F2FA2-23FD-427E-B1E8-2169C042E260
P2860
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Bisphosphonates in the managem ...... efficacy in clinical practice.
@en
type
label
Bisphosphonates in the managem ...... efficacy in clinical practice.
@en
prefLabel
Bisphosphonates in the managem ...... efficacy in clinical practice.
@en
P2860
P921
P356
P1476
Bisphosphonates in the managem ...... efficacy in clinical practice.
@en
P2093
Dieter Felsenberg
Oliver Bock
P2860
P304
P356
10.2147/CIA.S2134
P407
P577
2008-01-01T00:00:00Z